Stay updated on TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial

Sign up to get notified when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Added Gastric cancer topic and a new external resource link to the Genetic and Rare Diseases Information Center. Page revision updated from v3.4.1 to v3.4.2.
    Difference
    0.1%
    Check dated 2026-02-14T14:16:45.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A full citation for the TAGS trial (Lancet Oncol. 2018) was added to Publications, and the record version was updated from v3.4.0 (with an erratum) to v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-07T08:38:43.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    Added a 'Show glossary' toggle and updated the Revision label to v3.4.0. Minor wording changes to QC criteria status and FEAR Act data appear in the metadata.
    Difference
    0.1%
    Check dated 2026-01-24T02:53:56.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and v3.3.3 was removed.
    Difference
    0.0%
    Check dated 2026-01-17T00:53:29.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The Publications section was updated to replace the TAGS Lancet Oncol 2018 paper citation with the version that includes the erratum. The prior non-erratum citation was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-10T00:17:20.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Added locations across the US (Arizona, California, Florida, Illinois, Kentucky, Michigan, New Hampshire, New York, North Carolina, Pennsylvania, Rhode Island, Texas, Wisconsin) and international sites (Bavaria, Chiba, Gunma, Ibaraki, Osaka, Tochigi, Toyama, Porto District, Setúbal District, Dolj, Middlesex, Scotland), and removed several previously listed locations along with the HHS Vulnerability Disclosure link.
    Difference
    1%
    Check dated 2025-12-19T12:56:32.000Z thumbnail image

Stay in the know with updates to TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TAS-102 vs Placebo in Metastatic Gastric Cancer Clinical Trial page.